WO1996006605A1 - Method of reducing body fat in animals by the administration of conjugated linoleic acid - Google Patents
Method of reducing body fat in animals by the administration of conjugated linoleic acid Download PDFInfo
- Publication number
- WO1996006605A1 WO1996006605A1 PCT/US1995/006191 US9506191W WO9606605A1 WO 1996006605 A1 WO1996006605 A1 WO 1996006605A1 US 9506191 W US9506191 W US 9506191W WO 9606605 A1 WO9606605 A1 WO 9606605A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- animal
- linoleic acid
- conjugated linoleic
- cla
- body fat
- Prior art date
Links
- 229940108924 conjugated linoleic acid Drugs 0.000 title claims abstract description 58
- 241001465754 Metazoa Species 0.000 title claims abstract description 48
- 238000000034 method Methods 0.000 title claims abstract description 28
- OYHQOLUKZRVURQ-IXWMQOLASA-N linoleic acid Natural products CCCCC\C=C/C\C=C\CCCCCCCC(O)=O OYHQOLUKZRVURQ-IXWMQOLASA-N 0.000 title claims abstract description 25
- 210000000577 adipose tissue Anatomy 0.000 title claims abstract description 21
- JBYXPOFIGCOSSB-GOJKSUSPSA-N 9-cis,11-trans-octadecadienoic acid Chemical compound CCCCCC\C=C\C=C/CCCCCCCC(O)=O JBYXPOFIGCOSSB-GOJKSUSPSA-N 0.000 title claims abstract 11
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 16
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 16
- 230000037396 body weight Effects 0.000 claims description 6
- 235000013350 formula milk Nutrition 0.000 claims description 4
- 241000271566 Aves Species 0.000 claims description 2
- 241000124008 Mammalia Species 0.000 claims description 2
- 239000002960 lipid emulsion Substances 0.000 claims description 2
- 102000008934 Muscle Proteins Human genes 0.000 claims 2
- 108010074084 Muscle Proteins Proteins 0.000 claims 2
- 239000013589 supplement Substances 0.000 claims 2
- 238000001990 intravenous administration Methods 0.000 claims 1
- 239000000203 mixture Substances 0.000 description 22
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 21
- 241000699670 Mus sp. Species 0.000 description 14
- 231100000252 nontoxic Toxicity 0.000 description 12
- 230000003000 nontoxic effect Effects 0.000 description 12
- 241000282412 Homo Species 0.000 description 10
- 235000005911 diet Nutrition 0.000 description 10
- 230000037213 diet Effects 0.000 description 10
- 235000020778 linoleic acid Nutrition 0.000 description 10
- GKJZMAHZJGSBKD-UHFFFAOYSA-N (10E,12E)-Octadeca-9,11-dienoic acid Natural products CCCCCC=CC=CCCCCCCCCC(O)=O GKJZMAHZJGSBKD-UHFFFAOYSA-N 0.000 description 9
- JBYXPOFIGCOSSB-XBLVEGMJSA-N 9E,11E-octadecadienoic acid Chemical compound CCCCCC\C=C\C=C\CCCCCCCC(O)=O JBYXPOFIGCOSSB-XBLVEGMJSA-N 0.000 description 9
- OYHQOLUKZRVURQ-HZJYTTRNSA-N Linoleic acid Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC(O)=O OYHQOLUKZRVURQ-HZJYTTRNSA-N 0.000 description 9
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 9
- 241000030538 Thecla Species 0.000 description 9
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 9
- GKJZMAHZJGSBKD-BLHCBFLLSA-N (10e,12e)-octadeca-10,12-dienoic acid Chemical compound CCCCC\C=C\C=C\CCCCCCCCC(O)=O GKJZMAHZJGSBKD-BLHCBFLLSA-N 0.000 description 8
- GKJZMAHZJGSBKD-ANYPYVPJSA-N 10-trans-12-cis-linoleic acid Natural products CCCCCC=C\C=C\CCCCCCCCC(O)=O GKJZMAHZJGSBKD-ANYPYVPJSA-N 0.000 description 8
- 235000019197 fats Nutrition 0.000 description 8
- 239000002253 acid Substances 0.000 description 7
- 239000002285 corn oil Substances 0.000 description 7
- 235000005687 corn oil Nutrition 0.000 description 7
- 235000013305 food Nutrition 0.000 description 7
- 150000003839 salts Chemical class 0.000 description 7
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 6
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 6
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 6
- 239000002953 phosphate buffered saline Substances 0.000 description 6
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 5
- 241000282887 Suidae Species 0.000 description 5
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 5
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 5
- 150000007513 acids Chemical class 0.000 description 5
- 235000013372 meat Nutrition 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 239000003085 diluting agent Substances 0.000 description 4
- 239000000839 emulsion Substances 0.000 description 4
- 238000006317 isomerization reaction Methods 0.000 description 4
- 239000011734 sodium Substances 0.000 description 4
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 3
- 230000003203 everyday effect Effects 0.000 description 3
- 244000005700 microbiome Species 0.000 description 3
- 229910052757 nitrogen Inorganic materials 0.000 description 3
- 239000003921 oil Substances 0.000 description 3
- 235000019198 oils Nutrition 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 229910052708 sodium Inorganic materials 0.000 description 3
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- 235000019485 Safflower oil Nutrition 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 235000020940 control diet Nutrition 0.000 description 2
- 235000015872 dietary supplement Nutrition 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- 235000006486 human diet Nutrition 0.000 description 2
- 239000008024 pharmaceutical diluent Substances 0.000 description 2
- XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 description 2
- 239000003813 safflower oil Substances 0.000 description 2
- 235000005713 safflower oil Nutrition 0.000 description 2
- 235000021003 saturated fats Nutrition 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- 238000005303 weighing Methods 0.000 description 2
- OYHQOLUKZRVURQ-NTGFUMLPSA-N (9Z,12Z)-9,10,12,13-tetratritiooctadeca-9,12-dienoic acid Chemical compound C(CCCCCCC\C(=C(/C\C(=C(/CCCCC)\[3H])\[3H])\[3H])\[3H])(=O)O OYHQOLUKZRVURQ-NTGFUMLPSA-N 0.000 description 1
- 241000272525 Anas platyrhynchos Species 0.000 description 1
- 241000605900 Butyrivibrio fibrisolvens Species 0.000 description 1
- 208000005623 Carcinogenesis Diseases 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 102000004195 Isomerases Human genes 0.000 description 1
- 108090000769 Isomerases Proteins 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 229910001854 alkali hydroxide Inorganic materials 0.000 description 1
- 150000008044 alkali metal hydroxides Chemical class 0.000 description 1
- 235000019728 animal nutrition Nutrition 0.000 description 1
- 239000003005 anticarcinogenic agent Substances 0.000 description 1
- 229910052786 argon Inorganic materials 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 238000006701 autoxidation reaction Methods 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- 235000015278 beef Nutrition 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 230000036952 cancer formation Effects 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 231100000504 carcinogenesis Toxicity 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 235000001916 dieting Nutrition 0.000 description 1
- 230000037228 dieting effect Effects 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 235000012041 food component Nutrition 0.000 description 1
- 239000005417 food ingredient Substances 0.000 description 1
- 210000005095 gastrointestinal system Anatomy 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 235000020256 human milk Nutrition 0.000 description 1
- 230000002706 hydrostatic effect Effects 0.000 description 1
- 229940028435 intralipid Drugs 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 229940064696 nutrilipid Drugs 0.000 description 1
- JBYXPOFIGCOSSB-UHFFFAOYSA-N octadeca-9,11-dienoic acid Chemical class CCCCCCC=CC=CCCCCCCCC(O)=O JBYXPOFIGCOSSB-UHFFFAOYSA-N 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 235000016236 parenteral nutrition Nutrition 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 159000000001 potassium salts Chemical class 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 235000014059 processed cheese Nutrition 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 210000004767 rumen Anatomy 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008227 sterile water for injection Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
- 235000021122 unsaturated fatty acids Nutrition 0.000 description 1
- 150000004670 unsaturated fatty acids Chemical class 0.000 description 1
- 239000008215 water for injection Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
- A23C9/00—Milk preparations; Milk powder or milk powder preparations
- A23C9/12—Fermented milk preparations; Treatment using microorganisms or enzymes
- A23C9/123—Fermented milk preparations; Treatment using microorganisms or enzymes using only microorganisms of the genus lactobacteriaceae; Yoghurt
- A23C9/1234—Fermented milk preparations; Treatment using microorganisms or enzymes using only microorganisms of the genus lactobacteriaceae; Yoghurt characterised by using a Lactobacillus sp. other than Lactobacillus Bulgaricus, including Bificlobacterium sp.
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
- A23C9/00—Milk preparations; Milk powder or milk powder preparations
- A23C9/12—Fermented milk preparations; Treatment using microorganisms or enzymes
- A23C9/13—Fermented milk preparations; Treatment using microorganisms or enzymes using additives
- A23C9/1315—Non-milk proteins or fats; Seeds, pulses, cereals or soja; Fatty acids, phospholipids, mono- or diglycerides or derivatives therefrom; Egg products
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
- A23C9/00—Milk preparations; Milk powder or milk powder preparations
- A23C9/152—Milk preparations; Milk powder or milk powder preparations containing additives
- A23C9/1528—Fatty acids; Mono- or diglycerides; Petroleum jelly; Paraffine; Phospholipids; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23D—EDIBLE OILS OR FATS, e.g. MARGARINES, SHORTENINGS, COOKING OILS
- A23D7/00—Edible oil or fat compositions containing an aqueous phase, e.g. margarines
- A23D7/001—Spread compositions
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23D—EDIBLE OILS OR FATS, e.g. MARGARINES, SHORTENINGS, COOKING OILS
- A23D7/00—Edible oil or fat compositions containing an aqueous phase, e.g. margarines
- A23D7/005—Edible oil or fat compositions containing an aqueous phase, e.g. margarines characterised by ingredients other than fatty acid triglycerides
- A23D7/0056—Spread compositions
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K20/00—Accessory food factors for animal feeding-stuffs
- A23K20/10—Organic substances
- A23K20/158—Fatty acids; Fats; Products containing oils or fats
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K50/00—Feeding-stuffs specially adapted for particular animals
- A23K50/70—Feeding-stuffs specially adapted for particular animals for birds
- A23K50/75—Feeding-stuffs specially adapted for particular animals for birds for poultry
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/115—Fatty acids or derivatives thereof; Fats or oils
- A23L33/12—Fatty acids or derivatives thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/40—Complete food formulations for specific consumer groups or specific purposes, e.g. infant formula
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
- A61K31/201—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having one or two double bonds, e.g. oleic, linoleic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/11—Lactobacillus
- A23V2400/173—Reuteri
Definitions
- the present invention generally relates to animal nutrition. More particularly, it relates to a method of reducing body f t in an animal.
- CLA non-toxic salts thereof
- Our method is effective in reducing body fat in both mammals and avian species .
- the safe and effective amount of conjugated linoleic acid which is selected from 9, 11-octadecadienoic acid; 10,12- octadecadienoic acid; mixtures thereof; and non-toxic salts thereof is added to the feed of an animal in which it is desired to reduce the body fat.
- the amount of the conjugated linoleic acid to be added to the animal's feed will vary with the species and size of the animal. However, since the conjugated linoleic acids are natural food ingredients and relatively non-toxic, the amount which can be administered is not critical as long as it is enough to be effective.
- Nitrogen is bubbled into the ethylene glycol and KOH mixture for 20 in and the temperature is then raised to 180o C.
- reaction mixture is cooled to ambient conditions and 600 ml HCl is added to the mixture which is stirred for
- the mixture is transferred into a 4 L separatory funnel and extracted three times with 500-ml portions of hexane.
- the aqueous layer is drained and the combined hexane solution extracted with four 250-ml portions of 5% NaCl solution.
- the hexane is washed 3 times with water.
- the hexane is transferred to a flask and the moisture in the hexane removed with anhydrous sodium sulfate (Na 2 S0 ⁇ ).
- the hexane is filtered through Whatman paper into a clean 1000 ml round bottom flask and the hexane removed under vacuum with a rotoevaporator to obtain the CLA.
- the CLA is stored in a dark bottle under argon at -80o C until time of use.
- Example 2 Eight pigs (5 kg. body weight) are fed a standard control diet containing 0.5% corn oil and an equal number are fed the identical diet in which 0.5% of the corn oil is replaced by 0.5% CLA. Diet is provided free choice every day until the pigs are 15 kg. in weight. After the feeding period the pigs are sacrificed and the fat, protein, water and ash content of the carcasses is analyzed. It is found that the carcasses of the pigs fed the CLA diet contain less fat than the pigs fed the control diet.
- Example 3 The percentage of body fat of male humans, 20 to 45 years old, weighing approximately 10% over their recommended body weight, is determined by the method of body density by hydrostatic weighing. The humans are permitted to eat their usual diet to which 0.1 to 10 grams of CLA has been provided as a food supplement. After 4 to 10 weeks, the percentage of the body fat of the humans is again determined and it is found that the change in the percentage of body fat is reduced.
- Example 4 Thirty-two mice were fed either a control (5.5% Corn Oil) or a CLA (5% Corn Oil and 0.5% CLA) containing diet for 28 days. Fresh diet were provided every day. Animals were injected intraperitoneally with TNF- ⁇ (200 ⁇ g/kg body weight) or PBS (phosphate buffered saline). After 28 days the mice were sacrificed and the fat, protein, water and ash content of the carcasses analyzed.
- TNF- ⁇ 200 ⁇ g/kg body weight
- PBS phosphate buffered saline
- ECW Empty Carcass Weight. The results of the test show that although the overall weight of the control mice and the test mice was about the same, the total fat content of the test mice was significantly lower than that of the control mice. In addition, the percent of protein in the test mice injected with TNF- ⁇ was higher than in the control mice.
- the average body composition of the control and test mice (CLA) is shown in Table 2.
- mice were fed either control (5.5% Corn Oil) or CLA (5% Corn Oil and 0.5% CLA) containing diet for 28 days. Fresh diet were provided every day. Animals were injected intraperitoneally with TNF- ⁇ (200 ⁇ g/kg body weight) or PBS (phosphate buffered saline).
- free linoleic acid is administered to an animal which can convert the linoleic acid into CLA or which modulates the level of CLA in the body of an animal or a human.
- the linoleic acid is converted to CLA in the animal, probably by microorganisms in the animal's gastrointestinal system (S. F. Chin, J. M. Storkson, W. Liu, K. Albright, and M. W. Pariza, 1994, J. Nutr. 124: 694-701.
- the CLA can be administered to an animal in a pharmaceutical or veterinary composition, such as tablets, capsules, solutions or emulsions, containing safe and effective doses of the CLA.
- a pharmaceutical or veterinary composition such as tablets, capsules, solutions or emulsions, containing safe and effective doses of the CLA.
- the animal feeds and pharmaceutical or veterinary compositions for use in the method of the present invention are those containing the active forms of the free conjugated linoleic acids (CLA), especially 9,11-octadecadienoic acid and 10,12-octadecadienoic acid or mixtures thereof in combination with a conventional animal feed, human food supplement, or an approved pharmaceutical diluent.
- CLA free conjugated linoleic acids
- the active forms of CLA include, in addition to the free acids the active isomers of CLA; non-toxic salts thereof; active esters and other active chemical derivatives thereof; and mixtures thereof.
- CLA conjugated linoleic acids
- the free acid forms of the CLA may be prepared by isomerizing linoleic acid.
- conjuggated linoleic acids and "CLA” as used herein are intended to include 9,11-octadecadienoic acid, 10,12-octadecadienoic acid, mixtures thereof and the non-toxic salts of the acids.
- the non-toxic salts of the free acids may be made by reacting the free acids with a non-toxic base.
- CLA may also be prepared from linoleic acid by the action of a linoleic acid isomerase from a harmless microorganism, such as the Rumen bacterium Butyrivibrio fibrisolvens. Harmless microorganisms in the intestinal tracts of rats and other monogastric animals may also convert linoleic acid to CLA (S. F. Chin, J. M. Storkson, W. Liu, K. Albright and M. W. Pariza, 1994, J. Nutr. 124; 694-701.
- the CLA obtained by the practice of the described methods of preparation contains one or more of the 9,11- octadecadienoic acids and/or 10,12-octadecadienoic acids and active isomers thereof. It may be free or bound chemically through ester linkages.
- the CLA is heat stable and can be used as is, or dried and powdered.
- the CLA is readily converted into a non-toxic salt, such as the sodium or potassium salt, by reacting chemically equivalent amounts of the free acid with an alkali hydroxide at a pH of about 8 to 9.
- c9,tll- and tl0,cl2- isomers are predominantly produced during the autoxidation or alkali- isomerization of c9,cl2-linoleic acid due to the co-planar characteristics of 5 carbon atoms around a conjugated double-bond and spatial conflict of the resonance radical.
- the remaining two c,c-isomers are minor contributors.
- the relatively higher distribution of the t,t-isomers of 9,11- or 10,12-octadecadienoic acid apparently results from the further stabilization of c9,tll- or tl0,cl2- geometric isomers, which is thermodynamically preferred, during an extended processing time or long aging period. Additionally the t,t-isomer of 9,11- or 10,12- octadecadienoic acid that was predominantly formed during the isomerization of linoleic acid geometrical isomers (t9,tl2-, c9,tl2- and t9,cl2-octadecadienoic acid) may influence the final ratio of the isomers or the final CLA content in the samples.
- Linoleic acid geometrical isomers also influence the distribution of minor contributors (c,c-isomers of 9,11- and 10,12-, t9,cll- and ell ,tl2-octadecadienoic acids).
- the 11,13-isomer might be produced as a minor product from c9,cl2-octadecadienoic acid or from its isomeric forms during processing.
- the exact amount of CLA to be administered depends upon the animal, the form of CLA employed, and the route of administration. However, generally it will be an amount ranging from about 0.001 g/kg about 1 g/kg of the animals body weight.
- the amount employed of CLA employed as a pharmaceutical for humans will range from about 1,000 parts per million (ppm) to about 10,000 ppm of CLA of the human's diet.
- the upper limit of the amount to be employed is not critical because CLA is relatively non-toxic and it is a normal constituent of the human diet (including human breast milk) .
- the preferred pharmaceutical and veterinary composi ⁇ tions of CLA contain the non-toxic sodium or potassium salt of CLA in combination with a pharmaceutical diluent.
- a pharmaceutical diluent When the compositions are solutions or suspensions intended for oral administration the diluent will be one or more diluents, such as lactose or starch, and the product will be a tablet, capsule or liquid.
- the preferred diluent will be Sterile Water for Injection U.S.P.
- the amount of CLA to be added to an animal's feed to reduce body fat can range from .01% to 2.0% or more by weight of the animal's or human's food. It can be added to the food by adding either relatively pure CLA to the food or by adding by-products, such as the fat of an animal which was fed CLA, to the food.
- An especially preferred composition for use in humans might be a water in oil fat emulsion, such as Intralipid® (Baxter); Liposyn® (Abbott); Nutrilipid® (McGaw); or SoyaCal® (Alpha Therapeutic), in which about 0.5% to about 2% (preferably 1%) by weight of the oil has been replaced by CLA.
- These fat emulsions all contain emulsified fat particles of about 0.33-0.5 ⁇ m in diameter.
- the oils which are a mixture of neutral triglycerides of principally unsaturated fatty acids
- the emulsions contain Water for Injection USP as a diluent, egg phosphatides (1-2%) as an emulsifying agent and glycerin (2- 3%) to adjust toxicity.
- These emulsions can be infused intravenously to patients requiring parenteral nutrition.
- Another preferred composition is a baby formula, in which about 0.5% to about 2% by weight (preferably 0.5%) by weight of the fat content has been replaced by a like amount of CLA or to which 0.5% to about 2% by weight has been added.
Abstract
A method of reducing body fat comprises administering to the animal a safe and effective amount of a conjugated linoleic acid. Methods of preserving or increasing the animal's body protein by administering the conjugated linoleic acid also are disclosed.
Description
METHOD OF REDUCING BODY FAT IN ANIMALS BY THE ADMINISTRATION OF CONJUGATED LINOLEIC ACID.
Field of the Invention The present invention generally relates to animal nutrition. More particularly, it relates to a method of reducing body f t in an animal.
Background of the Invention
In today's health conscious society there is a great interest in the fat content of food. There is a special concern about the saturated fat content of meat because of its alleged relationship to blood cholesterol. As a result, most consumers would prefer to have meats of lower total and saturated fat content. As a result some meats, such as duck and beef, are declining in popularity.
There is an obvious need for a safe and effective method of reducing the body fat of animals, especially meat animals. There also is a great interest in dieting and other means of controlling the body fat of humans. There also is a need for preventing the loss of body protein in humans such as for example can occur when they are under attack of cytokines, such as tissue necrosis factor (TNF). As a result there also is a need for both a safe and an effective method for reducing the body fat of humans, and a need for a safe and an effective method of preventing the loss of body protein in humans.
Brief Summary of the Invention It is an object of the present invention to disclose a method of reducing body fat in an animal .
It is a further object to disclose a method of increasing body protein or preventing the loss of body protein in humans.
We have discovered a method of reducing body fat in an animal which comprises administering to said animal a safe amount of a compound selected from 9,11-octadecadienoic acid;
10, 12-octadecadienoic acid; mixtures thereof; and non-toxic salts thereof (CLA), which is effective to reduce body fat.
Our method is effective in reducing body fat in both mammals and avian species .
We also have discovered a method of increasing body protein or preventing the loss of body protein in a human which comprises administering to said animal a safe amount of a conjugated linoleic acid selected from 9,11-octadecadienoic acid; 10, 12-octadecadienoic acid; mixtures thereof; and non- toxic salts thereof, which is effective to increase and/or prevent the loss of body protein. It will be apparent to those skilled in the art that the forementioned objects and other advantages may be achieved by the practice of the present invention.
Description of the Preferred Embodiment
In one preferred embodiment of the method of the present invention the safe and effective amount of conjugated linoleic acid, which is selected from 9, 11-octadecadienoic acid; 10,12- octadecadienoic acid; mixtures thereof; and non-toxic salts
thereof is added to the feed of an animal in which it is desired to reduce the body fat. The amount of the conjugated linoleic acid to be added to the animal's feed will vary with the species and size of the animal. However, since the conjugated linoleic acids are natural food ingredients and relatively non-toxic, the amount which can be administered is not critical as long as it is enough to be effective.
The practice of the present invention is further illustrated by the examples which follow:
Example 1
SYNTHESIS OF CONJUGATED LINOLEIC ACIDS (CLA) FROM LINOLEIC ACID AND SAFFLOWER OIL
Ethylene glycol (1000 g) and 500 g potassium hydroxide
(KOH) are put into a 4-neck round bottom flask (5000 ml). The flask is equipped with a mechanical stirrer, a thermometer, a reflux condenser, and a nitrogen inlet. (The nitrogen introduced in first run through two oxygen traps).
Nitrogen is bubbled into the ethylene glycol and KOH mixture for 20 in and the temperature is then raised to 180o C.
1000 g of linoleic acid, corn oil, or safflower oil is then introduced into the flask. The mixture is heated at
180° C under an inert atmosphere for 2.5 hours.
The reaction mixture is cooled to ambient conditions and 600 ml HCl is added to the mixture which is stirred for
15 min. The pH of the mixture is adjusted to pH 3. Next,
200 ml of water is added into the mixture and stirred for
5 min. The mixture is transferred into a 4 L separatory
funnel and extracted three times with 500-ml portions of hexane.
The aqueous layer is drained and the combined hexane solution extracted with four 250-ml portions of 5% NaCl solution.
The hexane is washed 3 times with water. The hexane is transferred to a flask and the moisture in the hexane removed with anhydrous sodium sulfate (Na2S0ϋ). The hexane is filtered through Whatman paper into a clean 1000 ml round bottom flask and the hexane removed under vacuum with a rotoevaporator to obtain the CLA. The CLA is stored in a dark bottle under argon at -80o C until time of use.
Example 2 Eight pigs (5 kg. body weight) are fed a standard control diet containing 0.5% corn oil and an equal number are fed the identical diet in which 0.5% of the corn oil is replaced by 0.5% CLA. Diet is provided free choice every day until the pigs are 15 kg. in weight. After the feeding period the pigs are sacrificed and the fat, protein, water and ash content of the carcasses is analyzed. It is found that the carcasses of the pigs fed the CLA diet contain less fat than the pigs fed the control diet.
Example 3 The percentage of body fat of male humans, 20 to 45 years old, weighing approximately 10% over their recommended body weight, is determined by the method of body density by hydrostatic weighing. The humans are permitted to eat their
usual diet to which 0.1 to 10 grams of CLA has been provided as a food supplement. After 4 to 10 weeks, the percentage of the body fat of the humans is again determined and it is found that the change in the percentage of body fat is reduced.
Example 4 Thirty-two mice were fed either a control (5.5% Corn Oil) or a CLA (5% Corn Oil and 0.5% CLA) containing diet for 28 days. Fresh diet were provided every day. Animals were injected intraperitoneally with TNF-α (200 μg/kg body weight) or PBS (phosphate buffered saline). After 28 days the mice were sacrificed and the fat, protein, water and ash content of the carcasses analyzed.
Table 1.
Body Composition of Mice Fed 0.5% CLA Containing Diet for 28 days.1
Control CLA
PBS TNF-α PBS TNF-α
ECW (g)a 32.4 ± 1.1 31.9 ± 0.8 32.2 ± 0.8 31.6 ± 0.9
% Water 66.29 ± 0.78 66.61 ± 0.74 70.88 ± 0.38 71.19 ± 0.40
% Protein 17.76 ± 0.30 17.59 ± 0.23 18.58 ± 0.14 19.16 ± 0.06
% Fat 10.13 ± 1.17 9.36 ± 0.71 4.34 ± 0.40 3.66 ± 0.39
%Ash 3.08 ± 0.14 3.11 ± 0.04 3.24 ± 0.05 3.36 ± 0.04
1. Numbers are mean ± S.E. of 7-8 mice per group,
2. ECW: Empty Carcass Weight.
The results of the test show that although the overall weight of the control mice and the test mice was about the same, the total fat content of the test mice was significantly lower than that of the control mice. In addition, the percent of protein in the test mice injected with TNF-α was higher than in the control mice.
The average body composition of the control and test mice (CLA) is shown in Table 2.
Table 2.
Body Composition of Mice Fed 0.5% CLA Containing Diet for 28 days.1,2
Control CLA
ECW (g)3 32.1 ± 0.6 31.9 ± 0.6
% Water 66.46 ± 0.54 71.03 ± 0.28
% Protein 17.67 ± 0.19 18.87 ± 0.10
% Fat 9.72 ± 0.67 4.00 ± 0.29
%Ash 3.10 ± 0.03 3.30 ± 0.03
Mice were fed either control (5.5% Corn Oil) or CLA (5% Corn Oil and 0.5% CLA) containing diet for 28 days. Fresh diet were provided every day. Animals were injected intraperitoneally with TNF-α (200 μg/kg body weight) or PBS (phosphate buffered saline).
2, Numbers are mean ± S.E. of 15-16 mice per group. 3 ECW: Empty Carcass Weight.
In another embodiment of the invention, free linoleic acid is administered to an animal which can convert the
linoleic acid into CLA or which modulates the level of CLA in the body of an animal or a human. The linoleic acid is converted to CLA in the animal, probably by microorganisms in the animal's gastrointestinal system (S. F. Chin, J. M. Storkson, W. Liu, K. Albright, and M. W. Pariza, 1994, J. Nutr. 124: 694-701.
The method of the present invention may take other forms. For example, the CLA can be administered to an animal in a pharmaceutical or veterinary composition, such as tablets, capsules, solutions or emulsions, containing safe and effective doses of the CLA.
The animal feeds and pharmaceutical or veterinary compositions for use in the method of the present invention are those containing the active forms of the free conjugated linoleic acids (CLA), especially 9,11-octadecadienoic acid and 10,12-octadecadienoic acid or mixtures thereof in combination with a conventional animal feed, human food supplement, or an approved pharmaceutical diluent.
The active forms of CLA include, in addition to the free acids the active isomers of CLA; non-toxic salts thereof; active esters and other active chemical derivatives thereof; and mixtures thereof.
The free conjugated linoleic acids (CLA) have been previously isolated from fried meats and described as anticarcinogens by Y. L. Ha, N. K. Grimm and M. W. Pariza, in Carcinogenesis Vol. 8, No. 12, pp. 1881-1887 (1987). Since then, they have been found in some processed cheese products. Y. L. Ha, N. K. Grimm and M. W. Pariza, in J.
Agric. Food Chem. , Vol. 37, No. 1, pp. 75-81 (1987). However, animal feeds containing CLA, or its non-toxic derivatives, such as the sodium and potassium salts, as an additive in combination with conventional animal feeds or human foods are believed to be novel.
The free acid forms of the CLA may be prepared by isomerizing linoleic acid. The terms "conjugated linoleic acids" and "CLA" as used herein are intended to include 9,11-octadecadienoic acid, 10,12-octadecadienoic acid, mixtures thereof and the non-toxic salts of the acids. The non-toxic salts of the free acids may be made by reacting the free acids with a non-toxic base.
The preferred method of synthesizing CLA is that described in Example 1. However, CLA may also be prepared from linoleic acid by the action of a linoleic acid isomerase from a harmless microorganism, such as the Rumen bacterium Butyrivibrio fibrisolvens. Harmless microorganisms in the intestinal tracts of rats and other monogastric animals may also convert linoleic acid to CLA (S. F. Chin, J. M. Storkson, W. Liu, K. Albright and M. W. Pariza, 1994, J. Nutr. 124; 694-701.
The CLA obtained by the practice of the described methods of preparation contains one or more of the 9,11- octadecadienoic acids and/or 10,12-octadecadienoic acids and active isomers thereof. It may be free or bound chemically through ester linkages. The CLA is heat stable and can be used as is, or dried and powdered. The CLA is readily converted into a non-toxic salt, such as the sodium or
potassium salt, by reacting chemically equivalent amounts of the free acid with an alkali hydroxide at a pH of about 8 to 9.
Theoretically, 8 possible geometric isomers of 9,11- and 10,12-octadecadienoic acid (c9,cll; c9,tll; t9,cll; t9,tll; cl0,cl2; cl0,tl2; tl0,cl2 and tl0,tl2) would form from the isomerization of c9,cl2-octadecadienoic acid. As a result of the isomerization, only four isomers (c9,cll; c9,tll; tl0,cl2; and cl0,cl2) would be expected. However, of the four isomers, c9,tll- and tl0,cl2- isomers are predominantly produced during the autoxidation or alkali- isomerization of c9,cl2-linoleic acid due to the co-planar characteristics of 5 carbon atoms around a conjugated double-bond and spatial conflict of the resonance radical. The remaining two c,c-isomers are minor contributors.
The relatively higher distribution of the t,t-isomers of 9,11- or 10,12-octadecadienoic acid apparently results from the further stabilization of c9,tll- or tl0,cl2- geometric isomers, which is thermodynamically preferred, during an extended processing time or long aging period. Additionally the t,t-isomer of 9,11- or 10,12- octadecadienoic acid that was predominantly formed during the isomerization of linoleic acid geometrical isomers (t9,tl2-, c9,tl2- and t9,cl2-octadecadienoic acid) may influence the final ratio of the isomers or the final CLA content in the samples.
Linoleic acid geometrical isomers also influence the distribution of minor contributors (c,c-isomers of 9,11- and
10,12-, t9,cll- and ell ,tl2-octadecadienoic acids). The 11,13-isomer might be produced as a minor product from c9,cl2-octadecadienoic acid or from its isomeric forms during processing. The exact amount of CLA to be administered, of course, depends upon the animal, the form of CLA employed, and the route of administration. However, generally it will be an amount ranging from about 0.001 g/kg about 1 g/kg of the animals body weight. Generally, the amount employed of CLA employed as a pharmaceutical for humans will range from about 1,000 parts per million (ppm) to about 10,000 ppm of CLA of the human's diet. However, the upper limit of the amount to be employed is not critical because CLA is relatively non-toxic and it is a normal constituent of the human diet (including human breast milk) .
The preferred pharmaceutical and veterinary composi¬ tions of CLA contain the non-toxic sodium or potassium salt of CLA in combination with a pharmaceutical diluent. When the compositions are solutions or suspensions intended for oral administration the diluent will be one or more diluents, such as lactose or starch, and the product will be a tablet, capsule or liquid. When the compositions are solutions or suspensions intended for parenteral admini- stration the preferred diluent will be Sterile Water for Injection U.S.P.
The amount of CLA to be added to an animal's feed to reduce body fat can range from .01% to 2.0% or more by
weight of the animal's or human's food. It can be added to the food by adding either relatively pure CLA to the food or by adding by-products, such as the fat of an animal which was fed CLA, to the food. An especially preferred composition for use in humans might be a water in oil fat emulsion, such as Intralipid® (Baxter); Liposyn® (Abbott); Nutrilipid® (McGaw); or SoyaCal® (Alpha Therapeutic), in which about 0.5% to about 2% (preferably 1%) by weight of the oil has been replaced by CLA. These fat emulsions all contain emulsified fat particles of about 0.33-0.5 μm in diameter. In addition about 10% to 20% of the oils which are a mixture of neutral triglycerides of principally unsaturated fatty acids, the emulsions contain Water for Injection USP as a diluent, egg phosphatides (1-2%) as an emulsifying agent and glycerin (2- 3%) to adjust toxicity. These emulsions can be infused intravenously to patients requiring parenteral nutrition. Another preferred composition is a baby formula, in which about 0.5% to about 2% by weight (preferably 0.5%) by weight of the fat content has been replaced by a like amount of CLA or to which 0.5% to about 2% by weight has been added.
It will be readily apparent to those skilled in the art that a number of modifications or changes may be made without departing from the spirit and scope of the present invention. Therefore, the invention is only to be limited by the claims.
Claims
1. A method of reducing body fat in an animal comprises administering to the animal a safe amount of conjugated linoleic acid which is effective to reduce the body fat and the body protein of the animal.
2. The method of claim 1 in which the amount of conjugated linoleic acid administered is about 0.001 g/kg to about 1 g/kg of the animal's body weight.
3. A method of preserving body protein in an animal which comprises administering to said animal a safe and effective amount of conjugated linoleic acid to preserve body protein.
4. A method of increasing muscle protein in an animal which comprises administering to the animal a safe and effective amount of conjugated linoleic acid to increase muscle protein.
5. A method of modifying an animal feed, formula or supplement so that it reduces the body fat of an animal to which it is fed, which comprises adding to said animal feed, formula or supplement a safe amount of conjugated linoleic acid which when the feed is consumed by the animal will be effective to reduce its body fat.
6. The method of claim 4 in which the animal is a mammal.
7. The method of claim 4 in which the animal is an avian species.
8. A fat emulsion for intravenous or oral administration to which about 0.5% to about 2.0% of conjugated linoleic acid by weight has been added.
9. A baby formula to which about 0.5% to about 2% of conjugated linoleic acid by weight has been added.
10. A method of modifying an animal feed so that the body fat of the animal eating the feed will be reduced, said method comprising adding to said feed a safe amount of a conjugated linoleic acid which when consumed with the feed will be effective to reduce the animal's body fat.
Priority Applications (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP95920484A EP0731699B1 (en) | 1994-08-29 | 1995-05-12 | Method of reducing body fat in animals by the administration of conjugated linoleic acid |
AT95920484T ATE221377T1 (en) | 1994-08-29 | 1995-05-12 | METHOD FOR REDUCING BODY FAT IN ANIMALS USING THE ADMINISTRATION OF CONJUGATED LINOLIC ACID |
DE69527609T DE69527609T2 (en) | 1994-08-29 | 1995-05-12 | METHOD FOR REDUCING BODY FAT IN ANIMALS WITH THE ADMINISTRATION OF CONJUGATED LINOLIC ACID |
JP8508714A JP2992836B2 (en) | 1994-08-29 | 1995-05-12 | Method for reducing animal body fat by administering conjugated linoleic acid |
DK95920484T DK0731699T3 (en) | 1994-08-29 | 1995-05-12 | Method of reducing body fat in animals by administration of conjugated linoleic acid |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US08/297,472 US5554646A (en) | 1992-04-29 | 1994-08-29 | Method for reducing body fat in animals |
US08/297,472 | 1994-08-29 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1996006605A1 true WO1996006605A1 (en) | 1996-03-07 |
Family
ID=23146462
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US1995/006191 WO1996006605A1 (en) | 1994-08-29 | 1995-05-12 | Method of reducing body fat in animals by the administration of conjugated linoleic acid |
Country Status (8)
Country | Link |
---|---|
US (1) | US5554646A (en) |
EP (1) | EP0731699B1 (en) |
JP (1) | JP2992836B2 (en) |
AT (1) | ATE221377T1 (en) |
DE (1) | DE69527609T2 (en) |
DK (1) | DK0731699T3 (en) |
ES (1) | ES2180635T3 (en) |
WO (1) | WO1996006605A1 (en) |
Cited By (30)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1996038137A1 (en) * | 1995-06-02 | 1996-12-05 | Wisconsin Alumni Research Foundation | Methods for maintaining or elevating the cd-4 or cd-8 cell levels comprising the administration of conjugated linoleic acid; a new process for the manufacture of conjugated linoleic acid using lactobacillus sp |
EP0779033A1 (en) * | 1995-11-14 | 1997-06-18 | Unilever N.V. | Edible fat-spread |
WO1997046230A1 (en) * | 1996-06-07 | 1997-12-11 | Wisconsin Alumni Research Foundation | Method for maintaining an existing level of body fat and/or body weight |
WO1998005319A1 (en) * | 1996-08-07 | 1998-02-12 | Wisconsin Alumni Research Foundation | Methods of preventing skeletal problems in poultry |
WO1998048641A1 (en) * | 1997-04-25 | 1998-11-05 | Wisconsin Alumni Research Foundation | Method of increasing fat firmness and improving meat quality in animals |
WO1999012538A1 (en) * | 1997-09-05 | 1999-03-18 | Otsuka Pharmaceutical Co., Ltd. | Liver fat accumulation inhibitory composition, food additive for liver fat accumulation inhibition, and method of inhibiting liver fat accumulation |
US6060304A (en) * | 1995-06-01 | 2000-05-09 | Wisconsin Alumni Research Foundation | Method of producing conjugated fatty acids |
US6060087A (en) * | 1997-04-25 | 2000-05-09 | Wisconsin Alumni Research Foundation | Method of increasing fat firmness and improving meat quality in animals |
US6177580B1 (en) | 1998-04-21 | 2001-01-23 | Henkel Kommanditgesellschaft Auf Aktien | Conjugated linolenic acid-based synthetic triglycerides |
US6214372B1 (en) * | 1998-05-04 | 2001-04-10 | Con Lin Co., Inc. | Method of using isomer enriched conjugated linoleic acid compositions |
JP2002234838A (en) * | 1998-01-05 | 2002-08-23 | Natural Ltd As | Method for reducing body weight and treating obesity |
WO2002070014A1 (en) * | 2001-03-07 | 2002-09-12 | Natural Asa | Compositions comprising an o/w emulsion containing conjugated linoleic acid |
JP2002539807A (en) * | 1999-03-30 | 2002-11-26 | ウイスコンシン アラムナイ リサーチ フオンデーシヨン | How to selectively alter body fat levels, feed efficiency, or weight gain |
JP2003047439A (en) * | 1998-05-04 | 2003-02-18 | Conlinco Inc | Method for using isomer-enriched conjugated linoleic acid composition |
JP2003508479A (en) * | 1999-09-09 | 2003-03-04 | ペンタファルム・リミテッド | Use of conjugated linoleic acid (CLA) for topical treatment of cellulite |
US6762313B2 (en) | 2000-09-18 | 2004-07-13 | Cognis Deutschland Gmbh & Co. Kg | Processes for preparing linoleic acid raw materials for subsequent conjugation |
DE19718245C5 (en) * | 1997-04-30 | 2004-11-11 | Cognis Deutschland Gmbh & Co. Kg | Synthetic triglycerides based on conjugated linoleic acid, process for their preparation and their use |
US6881854B2 (en) | 2001-03-29 | 2005-04-19 | Basf Aktiengesellschaft | Conjugated unsaturated glyceride mixtures and a method for producing the same |
US7223543B2 (en) | 2001-06-08 | 2007-05-29 | Teagasc Dairy Products Research Centre | Conjugated linoleic acid isomerase and a process for the production of conjugated linoleic acid |
EP1791946A1 (en) * | 2004-09-02 | 2007-06-06 | PL Bio Co., Ltd. | Lactobacillus plantarum with body-fat reducing activity and the foods containing them |
WO2007074010A1 (en) | 2005-12-24 | 2007-07-05 | Teagasc Dairy Products Research Centre | Process for the production of trans-10, cis 12 octadecadienoic acid |
US7304089B2 (en) | 2001-01-17 | 2007-12-04 | Basf Aktiengesellschaft | Preparation for improved dietary utilisation |
US7700833B2 (en) | 2002-03-01 | 2010-04-20 | Cornell University | Process for the production of unsaturated fatty acids |
JP2010159304A (en) * | 2010-04-22 | 2010-07-22 | Aker Biomarin Asa | Method for reducing body weight and treating obesity |
WO2010118856A1 (en) * | 2009-04-17 | 2010-10-21 | Lipid Nutrition B.V. | Use of conjugated linoleic acid |
US8524309B2 (en) | 2004-04-28 | 2013-09-03 | Kao Corporation | Oil or fat composition |
US8853192B2 (en) | 2006-08-11 | 2014-10-07 | Kao Corporation | Fat or oil composition |
US9038103B2 (en) | 2005-05-06 | 2015-05-19 | Rovi Guides, Inc. | Systems and methods for content surfing |
US9185332B2 (en) | 2005-05-06 | 2015-11-10 | Rovi Guides, Inc. | Systems and methods for providing a scan |
US9544526B2 (en) | 2006-07-31 | 2017-01-10 | Rovi Guides, Inc. | Systems and methods for providing custom media content flipping |
Families Citing this family (97)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5760082C1 (en) * | 1994-08-29 | 2001-03-06 | Wisconsin Alumni Res Found | Dietetic foods containing conjugated linoleic acids |
US6595202B2 (en) | 1996-05-13 | 2003-07-22 | Universidad De Sevilla | Device and method for creating aerosols for drug delivery |
ES2140998B1 (en) * | 1996-05-13 | 2000-10-16 | Univ Sevilla | LIQUID ATOMIZATION PROCEDURE. |
US6299145B1 (en) | 1996-05-13 | 2001-10-09 | Universidad De Sevilla | Device and method for fluid aeration via gas forced through a liquid within an orifice of a pressure chamber |
US6187214B1 (en) | 1996-05-13 | 2001-02-13 | Universidad De Seville | Method and device for production of components for microfabrication |
US6792940B2 (en) * | 1996-05-13 | 2004-09-21 | Universidad De Sevilla | Device and method for creating aerosols for drug delivery |
US6189803B1 (en) | 1996-05-13 | 2001-02-20 | University Of Seville | Fuel injection nozzle and method of use |
US6405936B1 (en) | 1996-05-13 | 2002-06-18 | Universidad De Sevilla | Stabilized capillary microjet and devices and methods for producing same |
US6197835B1 (en) | 1996-05-13 | 2001-03-06 | Universidad De Sevilla | Device and method for creating spherical particles of uniform size |
US6386463B1 (en) | 1996-05-13 | 2002-05-14 | Universidad De Sevilla | Fuel injection nozzle and method of use |
US6196525B1 (en) | 1996-05-13 | 2001-03-06 | Universidad De Sevilla | Device and method for fluid aeration via gas forced through a liquid within an orifice of a pressure chamber |
US6015913A (en) * | 1996-09-06 | 2000-01-18 | Mars, Incorporated | Method for producing fat and/or solids from cocoa beans |
DE69719539D1 (en) * | 1996-11-05 | 2003-04-10 | Wisconsin Alumni Res Found | USE OF CONJUGATED LINOLIC ACID TO INCREASE THE ACTIVITY OF NATURAL KILLER LYMPHOCYTES |
US5855917A (en) * | 1996-12-04 | 1999-01-05 | Wisconsin Alumni Research Foundation | Method for controlling body fat and/or body weight in animals and pharmaceutical compositions for use therein comprising 20-carbon conjugated unsaturated fatty acids |
US6319950B1 (en) | 1997-02-18 | 2001-11-20 | Michael C. Seidel | Suppression of carcinoma using high purity conjugated linoleic acid (CLA) |
US5892074A (en) * | 1997-02-18 | 1999-04-06 | Seidel; Michael C. | Synthesis of conjugated linoleic acid (CLA) |
US6160141A (en) * | 1997-02-18 | 2000-12-12 | Seidel; Michael C. | Synthesis of conjugated eicosadienoic acid |
US6153774A (en) * | 1997-02-18 | 2000-11-28 | Seidel; Michael C. | Silver ion chromatography of high purity conjugated linoleic acid (CLA) |
US5885594A (en) * | 1997-03-27 | 1999-03-23 | The Procter & Gamble Company | Oral compositions having enhanced mouth-feel |
US7015249B1 (en) | 1997-12-12 | 2006-03-21 | Purdue Research Foundation | Methods and compositions for treating diabetes |
WO1999029317A1 (en) * | 1997-12-12 | 1999-06-17 | Purdue Research Foundation | Methods and compositions for treating diabetes |
JP2002508232A (en) | 1997-12-17 | 2002-03-19 | ユニバーシィダッド デ セビリヤ | Device and method for generating an aerosol for drug administration |
JPH11209279A (en) * | 1998-01-05 | 1999-08-03 | Natural Ltd As | Method for decreasing body weight and treating obesity |
US6042869A (en) | 1998-02-20 | 2000-03-28 | Natural Nutrition Ltd. | Bulk animal feeds containing conjugated linoleic acid |
US7078051B1 (en) * | 1998-08-11 | 2006-07-18 | Natural Asa | Conjugated linoleic acid alkyl esters in feedstuffs and food |
KR100619651B1 (en) | 1998-03-17 | 2006-09-05 | 콘린코 인크. | Conjugated linoleic acid compositions |
US7776353B1 (en) | 1998-03-17 | 2010-08-17 | Aker Biomarine Asa | Conjugated linoleic acid compositions |
US6015833A (en) | 1998-03-17 | 2000-01-18 | Conlinco., Inc. | Conjugated linoleic acid compositions |
US6113973A (en) * | 1998-04-15 | 2000-09-05 | Wisconsin Alumni Research Foundation | Eggs enriched with conjugated linoleic acid |
US6060514A (en) | 1998-05-04 | 2000-05-09 | Conlin Co., Inc. | Isomer enriched conjugated linoleic acid compositions |
US6696584B2 (en) | 1998-05-04 | 2004-02-24 | Natural Asa | Isomer enriched conjugated linoleic acid compositions |
US7101914B2 (en) * | 1998-05-04 | 2006-09-05 | Natural Asa | Isomer enriched conjugated linoleic acid compositions |
KR100313057B1 (en) * | 1998-05-26 | 2001-12-28 | 하영래 | Pork containing cla and method of raising pig therefor |
DE69943392D1 (en) * | 1998-08-20 | 2011-06-09 | Du Pont | GENES FOR FATTY ACID MODIFYING ENZYMES OF PLANTS AND ASSOCIATED EDUCATION OF CONJUGATED DOUBLE BINDINGS |
WO2000012080A1 (en) * | 1998-09-01 | 2000-03-09 | Amway Corporation | Diet composition and method of weight management |
US6316645B1 (en) | 1998-10-20 | 2001-11-13 | Wisconsin Alumni Research Foundation | Synthesis of conjugated polyunsaturated fatty acids |
US6450189B1 (en) | 1998-11-13 | 2002-09-17 | Universidad De Sevilla | Method and device for production of components for microfabrication |
US6129226A (en) * | 1999-02-08 | 2000-10-10 | Donovan; Timothy J. | Vehicle mounted mini hoist |
US6440931B1 (en) | 1999-02-23 | 2002-08-27 | Natural Corporation | Conjugated linoleic acid in treatment and prophylaxis of diabetes |
AU3843200A (en) * | 1999-04-27 | 2000-11-10 | Kabushiki Kaisha Yakult Honsha | Conjugated fatty acid esters |
US6077868A (en) * | 1999-07-20 | 2000-06-20 | Wisconsin Alumni Research Foundation | Selective inhibition of cyclooxygenase-2 |
DE60043701D1 (en) * | 1999-08-16 | 2010-03-04 | Du Pont | PROCESS FOR PREPARING CALENDULA ACID, A FATTY ACID WITH DELTA-8, 10, 12 CONJUGATED DOUBLE BINDINGS AND DIMORPHOLIC ACID, A FATTY ACID WITH A 9-HYDROXYL GROUP AND DELTA-10, 12 CONJUGATED DOUBLE BINDINGS |
GB2355382A (en) * | 1999-08-24 | 2001-04-25 | Gilbertson & Page Ltd | Conjugated linoleic acid for weight reduction in a dog |
US7947737B1 (en) | 1999-09-30 | 2011-05-24 | Aker Biomarine Asa | Method of treating hypertension and reducing serum lipase activity |
AU2118701A (en) | 1999-10-21 | 2001-04-30 | Board Of Regents For Oklahoma State University, The | Sterol esters of conjugated linoleic acids and process for their production |
US6420577B1 (en) | 1999-12-01 | 2002-07-16 | Her Majesty The Queen In Right Of Canada, As Represented By The Minister Of Agriculture | Method for commercial preparation of conjugated linoleic acid |
US6432469B1 (en) | 2000-02-17 | 2002-08-13 | Natural Corporation | Bulk animal feeds containing conjugated linoleic acid |
CA2398940C (en) * | 2000-02-24 | 2012-02-21 | Xenon Genetics, Inc. | Methods and compositions using stearoyl-coa desaturase to identify triglyceride reducing therapeutic agents |
US20030064950A1 (en) * | 2001-02-23 | 2003-04-03 | Ntambi James M. | Methods for reducing body fat and increasing lean body mass by reducing stearoyl-CoA desaturase 1 activity |
NO328803B1 (en) * | 2000-03-03 | 2010-05-18 | Thia Medica | New fatty acid analogues |
US6482434B1 (en) | 2000-04-04 | 2002-11-19 | Wisconsin Alumni Research Foundation | Method for reducing adverse effects of a weight loss regimen |
CA2404799C (en) * | 2000-04-06 | 2007-08-07 | Conlinco, Inc. | Conjugated linoleic acid compositions |
US20030149288A1 (en) * | 2000-04-18 | 2003-08-07 | Natural Asa | Conjugated linoleic acid powder |
WO2001078531A2 (en) | 2000-04-18 | 2001-10-25 | Natural As | Conjugated linoleic acid powder |
US6380409B1 (en) * | 2000-04-24 | 2002-04-30 | Conlin Co., Inc. | Methods for preparing CLA isomers |
EP1357977B1 (en) * | 2000-09-21 | 2004-07-21 | Nutrition 21, Inc. | Chromium containing compositions for the treatment of diabetes, the reduction of body fat, improvement of insulin sensitivity and reduction of hyperglycemia and hypercholesteremia |
US6395782B1 (en) | 2001-03-02 | 2002-05-28 | Wisconsin Alumni Research Foundation | Method of increasing longevity and preventing body weight wasting in autoimmune disease by using conjugated linoleic acid |
US6479683B1 (en) | 2001-03-06 | 2002-11-12 | Ag Processing Inc | Process for conjugating fatty acid esters |
EP1408945A4 (en) | 2001-03-27 | 2005-07-06 | Univ California | Methods, compounds, and compositions for reducing body fat and modulating fatty acid metabolism |
KR20020081632A (en) * | 2001-04-19 | 2002-10-30 | (주)라이브맥스 | Preparation Method for CLA-enriched Structured Lipid and The Same Use |
US7365099B2 (en) | 2001-05-31 | 2008-04-29 | Wisconsin Alumni Research Foundation | Animal body fat control |
US7098352B2 (en) * | 2001-11-16 | 2006-08-29 | Virtus Nutrition Llc | Calcium salt saponification of polyunsaturated oils |
US6677470B2 (en) | 2001-11-20 | 2004-01-13 | Natural Asa | Functional acylglycerides |
US6414171B1 (en) | 2001-11-27 | 2002-07-02 | Her Majesty In Right Of Canada, As Represented By The Minister Of Agriculture & Agri-Food Canada | Method for commercial preparation of conjugated linoleic acid from by-products of vegetable oil refining |
US6409649B1 (en) | 2001-11-27 | 2002-06-25 | Her Majesty The Queen In Right Of Canada, As Represented By The Minister Of Agriculture & Agri-Food Canada | Method for commercial preparation of conjugated linoleic acid using recycled alkali transesterification catalyst |
AU2003205279B2 (en) * | 2002-01-22 | 2007-08-23 | Mars, Incorporated | Weight management system for obese animals |
US20030138547A1 (en) * | 2002-01-22 | 2003-07-24 | Mars, Incorporated | Weight management system for animals |
US20040248977A1 (en) * | 2002-02-22 | 2004-12-09 | Elliot Block | Rapid growth dairy heifers having reduced mammary fat content |
CA2396840A1 (en) * | 2002-08-06 | 2004-02-06 | Juan Miguel Garro Galvez | New conjugated linolenic acids and methods for commercial preparation, purification and uses |
AU2003296895A1 (en) * | 2002-08-20 | 2004-05-04 | The Regents Of The University Of California | Combination therapy for controlling appetites |
US6743931B2 (en) | 2002-09-24 | 2004-06-01 | Natural Asa | Conjugated linoleic acid compositions |
WO2004045307A2 (en) * | 2002-11-18 | 2004-06-03 | Natural Asa | Dietry supplements and foods product comprising oleylethanolamide |
US20040202732A1 (en) * | 2003-04-11 | 2004-10-14 | Brown William Stewart | Composition to promote weight loss |
US6897327B2 (en) * | 2003-05-08 | 2005-05-24 | Stepan Company | Manufacture of conjugated linoleic salts and acids |
US20040228948A1 (en) * | 2003-05-16 | 2004-11-18 | Kennelly John J. | Increasing the concentration of conjugated linoleic acid isomers in the milk fat and/or tissue fat of ruminants |
CA2436650A1 (en) * | 2003-08-06 | 2005-02-06 | Naturia Inc. | Conjugated linolenic acid (clnatm) compositions: synthesis, purification and uses |
US20050069593A1 (en) * | 2003-09-29 | 2005-03-31 | Life Time Fitness, Inc. | Nutritional supplement containing 7-Keto-DHEA and conjugated linoleic acid |
JP2007509066A (en) * | 2003-10-16 | 2007-04-12 | ザ・レジェンツ・オブ・ザ・ユニバーシティ・オブ・カリフォルニア | Food and other compositions, compounds and methods for reducing body fat, suppressing appetite and regulating fatty acid metabolism |
AU2003299920A1 (en) * | 2003-12-23 | 2005-08-03 | Stepan Company | Production and purification of esters of conjugated linoleic acids |
EP1570752B1 (en) * | 2004-03-06 | 2008-07-02 | Cognis IP Management GmbH | Verwendung von ungesättigten Fettsäuren zur Verringerung des Appetits oder der Essensaufnahme |
JP5283902B2 (en) * | 2004-03-17 | 2013-09-04 | ネステク ソシエテ アノニム | Composition or method for reducing or preventing obesity |
EP1765964A4 (en) * | 2004-04-30 | 2007-11-07 | Polyunsaturated fatty acid monovalent and divalent metal salt synthesis | |
ES2258928A1 (en) * | 2005-02-25 | 2006-09-01 | Aceites Borges Pont, S.A. | Set of vegetable oils and conjugate linoleic acid based food compositions comprises a nutritional blend countering body fat loss, and providing flavour |
ES2296438B1 (en) * | 2005-03-04 | 2009-03-16 | Corporacion Alimentaria Peñasanta, S.A. | FUNCTIONAL FOOD BASED ON AN UNFERMENTED DAIRY PRODUCT AND CONJUGATED LINOLEIC ACID. |
ES2299288B1 (en) * | 2005-03-04 | 2009-04-16 | Corporacion Alimentaria Peñasanta, S.A. | FUNCTIONAL FOOD BASED ON A NON-FERMENTED DAIRY PRODUCT COMBINED WITH FRUIT JUICE AND CONJUGATED LINOLEIC ACID. |
EP1919954B1 (en) | 2005-08-30 | 2016-10-19 | University of Miami | Immunomodulating tumor necrosis factor receptor 25 (tnfr25) agonists, antagonists and immunotoxins |
CN101291596A (en) | 2005-11-02 | 2008-10-22 | 雀巢技术公司 | Isoflavone compositions for reducing accumulation of body fat in male mammals, and methods for their use |
DE602006016476D1 (en) * | 2005-12-05 | 2010-10-07 | Stepan Co | PROCESS FOR THE PREPARATION OF CONJUGATED LINOLIC ACID AND DERIVATIVES THEREOF FROM RICINOLIC ACID |
DE102007009650A1 (en) | 2007-02-26 | 2008-08-28 | Beiersdorf Ag | Cosmetic combination product to improve the external appearance |
DE102007009649A1 (en) | 2007-02-26 | 2008-08-28 | Beiersdorf Ag | Food supplement for cosmetic care and treatment of the skin, contains at least two cosmetically-active substances, especially conjugated linoleic acid, L-carnitine or its derivatives and-or mate tea extract |
WO2008112661A2 (en) | 2007-03-09 | 2008-09-18 | Alexza Pharmaceuticals, Inc. | Heating unit for use in a drug delivery device |
KR101087275B1 (en) * | 2007-10-02 | 2011-12-05 | 대한민국(농촌진흥청장) | Method of preparing conjugated linoleic acid from bio diesel byproduct and composition comprising thereof |
WO2009158248A2 (en) * | 2008-06-25 | 2009-12-30 | Elc Management Llc | Method and compositions for improving skin and body appearance |
US20120048963A1 (en) | 2010-08-26 | 2012-03-01 | Alexza Pharmaceuticals, Inc. | Heat Units Using a Solid Fuel Capable of Undergoing an Exothermic Metal Oxidation-Reduction Reaction Propagated without an Igniter |
KR102217768B1 (en) | 2015-03-11 | 2021-02-19 | 알렉스자 파마스티칼즈, 인크. | Use of antistatic materials in airways for thermal aerosol condensation processes |
US11638434B2 (en) * | 2017-12-06 | 2023-05-02 | Elanco Us Inc. | Feed additive compositions |
US20230348951A1 (en) | 2022-04-28 | 2023-11-02 | Société des Produits Nestlé S.A. | Diagnosing and treating chronic kidney disease in a feline |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4282265A (en) * | 1980-01-14 | 1981-08-04 | Bristol-Myers Company | Fat compositions for infant formulas |
EP0376628A2 (en) * | 1988-12-29 | 1990-07-04 | American Home Products Corporation | Fat composition for infant formulas |
WO1992001450A1 (en) * | 1990-07-16 | 1992-02-06 | Lipotech Partners Limited Partnership | Food and pharmaceutical compositions containing short chain monounsaturated fatty acids and methods of using |
EP0579901A1 (en) * | 1992-04-29 | 1994-01-26 | Wisconsin Alumni Research Foundation | Use of a feed additive for preventing weight loss, reduction in weight gain, and anorexia due to immune stimulation |
WO1994016690A1 (en) * | 1993-01-22 | 1994-08-04 | Wisconsin Alumni Research Foundation | Method for increasing the efficiency of feed conversion in animals |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4603142A (en) * | 1984-06-01 | 1986-07-29 | Wisconsin Alumni Research Foundation | Cholesterol lowering method of use |
JPS61294982A (en) * | 1985-06-22 | 1986-12-25 | Csk Corp | Communication system for character information in catv |
JPS6398355A (en) * | 1986-10-16 | 1988-04-28 | Kazumitsu Maruta | Feed for animal |
US5070104A (en) * | 1989-02-17 | 1991-12-03 | Wisconsin Alumni Research Foundation | Methods of chelating metal and novel compositions therefor |
US5017614A (en) * | 1989-02-17 | 1991-05-21 | Wisconsin Alumni Research Foundation | Methods of preventing oxidation, quenching singlet oxygen and inhibiting mold growth and novel compositions therefor |
US5162337A (en) * | 1990-10-05 | 1992-11-10 | Merck & Co., Inc. | Animal growth promotion |
US5443844A (en) * | 1992-12-03 | 1995-08-22 | Mcdaniel; William R. | Linoleic acid preparations for topical treatment of acne vulgaris |
US5484623A (en) * | 1994-01-10 | 1996-01-16 | Mclean; Linsey | Dietary system high in oil intake for the treatment of obesity and for the lowering of saturated fats |
-
1994
- 1994-08-29 US US08/297,472 patent/US5554646A/en not_active Expired - Lifetime
-
1995
- 1995-05-12 EP EP95920484A patent/EP0731699B1/en not_active Expired - Lifetime
- 1995-05-12 DK DK95920484T patent/DK0731699T3/en active
- 1995-05-12 WO PCT/US1995/006191 patent/WO1996006605A1/en active IP Right Grant
- 1995-05-12 JP JP8508714A patent/JP2992836B2/en not_active Expired - Lifetime
- 1995-05-12 ES ES95920484T patent/ES2180635T3/en not_active Expired - Lifetime
- 1995-05-12 AT AT95920484T patent/ATE221377T1/en active
- 1995-05-12 DE DE69527609T patent/DE69527609T2/en not_active Expired - Lifetime
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4282265A (en) * | 1980-01-14 | 1981-08-04 | Bristol-Myers Company | Fat compositions for infant formulas |
EP0376628A2 (en) * | 1988-12-29 | 1990-07-04 | American Home Products Corporation | Fat composition for infant formulas |
WO1992001450A1 (en) * | 1990-07-16 | 1992-02-06 | Lipotech Partners Limited Partnership | Food and pharmaceutical compositions containing short chain monounsaturated fatty acids and methods of using |
EP0579901A1 (en) * | 1992-04-29 | 1994-01-26 | Wisconsin Alumni Research Foundation | Use of a feed additive for preventing weight loss, reduction in weight gain, and anorexia due to immune stimulation |
WO1994016690A1 (en) * | 1993-01-22 | 1994-08-04 | Wisconsin Alumni Research Foundation | Method for increasing the efficiency of feed conversion in animals |
Non-Patent Citations (4)
Title |
---|
CHIN ET AL: "conjugated dienoic derivatives of linoleic acid; a new class of food-derived acid", ACS SYMPOSIUM SERIES, vol. 528, pages 262 - 71 * |
CHIN ET AL: "conjugated linoleic acid (9,11- and 10,12-octadecadienoic acid) is produced in conventional but not germ-free rats fed linoleic acid", J. OF NUTRITION, vol. 124, no. 5, pages 694 - 701 * |
FOGERTY ET AL: "octadeca-9,11-dienoic acid in foodstuffs and in the lipids of human blood and breast milk", NUTRITION REPORTS INTERNATIONAL, vol. 38, no. 5, pages 937 - 44 * |
MILLER ET AL: "feeding conjugated linoleic acid to animals partially overcome catabolic responses due to endotoxin injection", BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, vol. 198, no. 3, 15 February 1994 (1994-02-15), pages 1107 - 12 * |
Cited By (46)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5827885A (en) * | 1992-04-29 | 1998-10-27 | Wisconsin Alumni Research Foundation | Methods of treating animals to maintain or increase CD-4 and CD-8 cell populations |
US6020376A (en) * | 1995-06-01 | 2000-02-01 | Wisconsin Alumni Research Foundation | Methods of treating animals to maintain or increase CD-4 and CD-8 cell populations |
US6060304A (en) * | 1995-06-01 | 2000-05-09 | Wisconsin Alumni Research Foundation | Method of producing conjugated fatty acids |
WO1996038137A1 (en) * | 1995-06-02 | 1996-12-05 | Wisconsin Alumni Research Foundation | Methods for maintaining or elevating the cd-4 or cd-8 cell levels comprising the administration of conjugated linoleic acid; a new process for the manufacture of conjugated linoleic acid using lactobacillus sp |
EP0779033A1 (en) * | 1995-11-14 | 1997-06-18 | Unilever N.V. | Edible fat-spread |
WO1997046230A1 (en) * | 1996-06-07 | 1997-12-11 | Wisconsin Alumni Research Foundation | Method for maintaining an existing level of body fat and/or body weight |
EP1438898A3 (en) * | 1996-06-07 | 2005-01-05 | Wisconsin Alumni Research Foundation | Method for maintaining an existing level of body fat and/or body weight |
EP1438898A2 (en) * | 1996-06-07 | 2004-07-21 | Wisconsin Alumni Research Foundation | Method for maintaining an existing level of body fat and/or body weight |
WO1998005319A1 (en) * | 1996-08-07 | 1998-02-12 | Wisconsin Alumni Research Foundation | Methods of preventing skeletal problems in poultry |
WO1998048641A1 (en) * | 1997-04-25 | 1998-11-05 | Wisconsin Alumni Research Foundation | Method of increasing fat firmness and improving meat quality in animals |
US5851572A (en) * | 1997-04-25 | 1998-12-22 | Wisconsin Alumni Research Foundation | Method of increasing fat firmness and improving meat quality in animals with conjugated linolenic acid |
US6060087A (en) * | 1997-04-25 | 2000-05-09 | Wisconsin Alumni Research Foundation | Method of increasing fat firmness and improving meat quality in animals |
DE19718245C5 (en) * | 1997-04-30 | 2004-11-11 | Cognis Deutschland Gmbh & Co. Kg | Synthetic triglycerides based on conjugated linoleic acid, process for their preparation and their use |
WO1999012538A1 (en) * | 1997-09-05 | 1999-03-18 | Otsuka Pharmaceutical Co., Ltd. | Liver fat accumulation inhibitory composition, food additive for liver fat accumulation inhibition, and method of inhibiting liver fat accumulation |
US6468556B1 (en) | 1997-09-05 | 2002-10-22 | Otsuka Pharmaceutical Co., Ltd. | Liver fat accumulation inhibitory composition, food additive for liver fat accumulation, inhibition, and method of inhibiting liver fat accumulation |
JP2002234838A (en) * | 1998-01-05 | 2002-08-23 | Natural Ltd As | Method for reducing body weight and treating obesity |
US6177580B1 (en) | 1998-04-21 | 2001-01-23 | Henkel Kommanditgesellschaft Auf Aktien | Conjugated linolenic acid-based synthetic triglycerides |
JP2015037410A (en) * | 1998-05-04 | 2015-02-26 | ナチュラル アルメン アクシェセルスカプ | Method of use of isomer concentrated conjugated linoleic acid composition |
JP2003047439A (en) * | 1998-05-04 | 2003-02-18 | Conlinco Inc | Method for using isomer-enriched conjugated linoleic acid composition |
JP2010259437A (en) * | 1998-05-04 | 2010-11-18 | Natural Asa | Methods of using isomer enriched conjugated linoleic acid compositions |
JP2003113080A (en) * | 1998-05-04 | 2003-04-18 | Conlinco Inc | Method for using conjugated linoleic acid composition of which isomers are concentrated |
JP2010195825A (en) * | 1998-05-04 | 2010-09-09 | Natural Asa | Method of using isomer-enriched conjugated linoleic acid composition |
JP2015044810A (en) * | 1998-05-04 | 2015-03-12 | ナチュラル アルメン アクシェセルスカプ | Method of use of isomer concentrated conjugated linoleic acid composition |
US6214372B1 (en) * | 1998-05-04 | 2001-04-10 | Con Lin Co., Inc. | Method of using isomer enriched conjugated linoleic acid compositions |
WO2000035300A1 (en) * | 1998-12-16 | 2000-06-22 | Wisconsin Alumni Research Foundation | Method of increasing fat firmness and improving meat quality in animals |
JP2002539807A (en) * | 1999-03-30 | 2002-11-26 | ウイスコンシン アラムナイ リサーチ フオンデーシヨン | How to selectively alter body fat levels, feed efficiency, or weight gain |
JP2003508479A (en) * | 1999-09-09 | 2003-03-04 | ペンタファルム・リミテッド | Use of conjugated linoleic acid (CLA) for topical treatment of cellulite |
US6762313B2 (en) | 2000-09-18 | 2004-07-13 | Cognis Deutschland Gmbh & Co. Kg | Processes for preparing linoleic acid raw materials for subsequent conjugation |
US7304089B2 (en) | 2001-01-17 | 2007-12-04 | Basf Aktiengesellschaft | Preparation for improved dietary utilisation |
WO2002070014A1 (en) * | 2001-03-07 | 2002-09-12 | Natural Asa | Compositions comprising an o/w emulsion containing conjugated linoleic acid |
US8349894B2 (en) | 2001-03-07 | 2013-01-08 | Aker Biomarine Asa | Compositions comprising an o/w emulsion containing conjugated linoleic acid |
AU2002238710B2 (en) * | 2001-03-07 | 2007-09-06 | Natural Asa | Compositions comprising an o/w emulsion containing conjugated linoleic acid |
US6881854B2 (en) | 2001-03-29 | 2005-04-19 | Basf Aktiengesellschaft | Conjugated unsaturated glyceride mixtures and a method for producing the same |
US7223543B2 (en) | 2001-06-08 | 2007-05-29 | Teagasc Dairy Products Research Centre | Conjugated linoleic acid isomerase and a process for the production of conjugated linoleic acid |
US7700833B2 (en) | 2002-03-01 | 2010-04-20 | Cornell University | Process for the production of unsaturated fatty acids |
US8524309B2 (en) | 2004-04-28 | 2013-09-03 | Kao Corporation | Oil or fat composition |
EP1791946A4 (en) * | 2004-09-02 | 2008-01-09 | Pl Bio Co Ltd | Lactobacillus plantarum with body-fat reducing activity and the foods containing them |
EP1791946A1 (en) * | 2004-09-02 | 2007-06-06 | PL Bio Co., Ltd. | Lactobacillus plantarum with body-fat reducing activity and the foods containing them |
US9185332B2 (en) | 2005-05-06 | 2015-11-10 | Rovi Guides, Inc. | Systems and methods for providing a scan |
US9038103B2 (en) | 2005-05-06 | 2015-05-19 | Rovi Guides, Inc. | Systems and methods for content surfing |
WO2007074010A1 (en) | 2005-12-24 | 2007-07-05 | Teagasc Dairy Products Research Centre | Process for the production of trans-10, cis 12 octadecadienoic acid |
US9544526B2 (en) | 2006-07-31 | 2017-01-10 | Rovi Guides, Inc. | Systems and methods for providing custom media content flipping |
US8853192B2 (en) | 2006-08-11 | 2014-10-07 | Kao Corporation | Fat or oil composition |
US9149050B2 (en) | 2009-04-17 | 2015-10-06 | Stepan Specialty Products, Llc | Use of conjugated linoleic acid |
WO2010118856A1 (en) * | 2009-04-17 | 2010-10-21 | Lipid Nutrition B.V. | Use of conjugated linoleic acid |
JP2010159304A (en) * | 2010-04-22 | 2010-07-22 | Aker Biomarin Asa | Method for reducing body weight and treating obesity |
Also Published As
Publication number | Publication date |
---|---|
US5554646A (en) | 1996-09-10 |
JP2992836B2 (en) | 1999-12-20 |
DE69527609D1 (en) | 2002-09-05 |
ES2180635T3 (en) | 2003-02-16 |
JPH10508189A (en) | 1998-08-18 |
ATE221377T1 (en) | 2002-08-15 |
DE69527609T2 (en) | 2003-03-20 |
EP0731699A1 (en) | 1996-09-18 |
DK0731699T3 (en) | 2002-12-02 |
EP0731699B1 (en) | 2002-07-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US5554646A (en) | Method for reducing body fat in animals | |
EP0909132B1 (en) | Dietetic baby food formula containing conjugated linoleic acids | |
EP0907360B1 (en) | Method for maintaining an existing level of body fat and/or body weight | |
US5430066A (en) | Methods for preventing weight loss, reduction in weight gain, and anorexia due to immune stimulation | |
JP2745245B2 (en) | How to increase animal feeding efficiency | |
US5804210A (en) | Methods of treating animals to maintain or enhance bone mineral content and compositions for use therein | |
EP0918516B1 (en) | Methods of preventing skeletal problems in poultry | |
EP0977492B1 (en) | Method of increasing fat firmness and improving meat quality in animals | |
US6242621B1 (en) | Isomer enriched conjugated linoleic acid compositions | |
US6214372B1 (en) | Method of using isomer enriched conjugated linoleic acid compositions | |
AU771921B2 (en) | Method for selectively altering body fat level, feed efficiency, or weight gain | |
US6852757B2 (en) | Isomer enriched conjugated linoleic acid compositions | |
US6696584B2 (en) | Isomer enriched conjugated linoleic acid compositions |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): JP |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1995920484 Country of ref document: EP |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWP | Wipo information: published in national office |
Ref document number: 1995920484 Country of ref document: EP |
|
WWG | Wipo information: grant in national office |
Ref document number: 1995920484 Country of ref document: EP |